top of page
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, Stephen D.; Raz, Itamar; Bonaca, Marc P.; Mosenzon, Ofri; Kato, Eri T.; Cahn, Avivit; Silverman, Michael G.; Zelniker, Thomas A.; Kuder, Julia F.; Murphy, Sabina A.; Bhatt, Deepak L.; Leiter, Lawrence A.; McGuire, Darren K.; Wilding, John P.H.; Ruff, Christian T.; Gause-Nilsson, Ingrid A.M.; Fredriksson, Martin; Johansson, Peter A.; Langkilde, Anna-Maria; Sabatine, Marc S.
Abstract:
To the Editor: Although the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) reported by Green et al. (July 16 issue)1 provides valuable data, we have concerns about within-trial differences in glycemic control and medication that could have biased the results in favor of sitagliptin. In this trial, patients who received placebo, as compared with patients who received sitagliptin, received a greater number of conventional therapies for diabetes.1 Thiazolidinediones may cause heart failure, and insulin and sulfonylureas may not be without risk.2 Therefore, the lack of a heart-failure signal could be falsely reassuring. Can the authors describe the use of medications . . .
Automatic Tags
bottom of page